



## Sheffield Haemophilia and Thrombosis Centre

Dr M Makris  
Dr K K Hampton  
Dr R M Maclean  
Dr J J van Veen  
Prof I R Peake (Genetics)  
Dr A C Goodeve (Genetics)  
Dr S Kitchen (Laboratory)

Royal Hallamshire Hospital  
Glossop Road  
Sheffield S10 2JF  
Tel: 44 (0)114 271 3211  
Fax: 44 (0)114 275 6126

Dr M Makris: **GRO-C**  
Secretary: **GRO-C**  
E-mail: claire.warsop@ **GRO-C**

Our reference: **GRO-C**

1 September 2010 (Dictated: 30 July 2010)

Mrs L Dewhurst  
National Haemophilia Database  
UKHCDO  
The Works  
5 Union Street  
Manchester M12 4JD

Dear Lynne

**Re: Incorrectly labelled patients as being "at risk" of new variant CJD**

Following the recent issue with the batches of BPL products made from American plasma and the incorrect information of patients being in the "at risk" group of new variant CJD, we have now looked through all our data. We have identified six individuals who we labelled as being in the "at risk" group but who have had only factors made from American plasma in Sheffield. Before we inform the patients of their change in category, I would be grateful if you could confirm that you have not been informed by any other Haemophilia Centre in the UK that these patients were in the "at risk" group due to previous exposure. Please find attached two pages regarding the relevant information. As far as I can see, our patients can be sub-divided into three groups:

- A. Sheffield patients. We think **GRO-A** and **GRO-A** probably only had concentrate in Sheffield but would be grateful if you could confirm this.
- B. **GRO-A** is a patient from the Royal Free Hospital who had surgery in Sheffield. It is possible that she may have had previous UK products at the Royal Free Hospital and I would be grateful if you could confirm or deny this.
- C. Finally, we have two patients **GRO-A** and **GRO-A** who were students at the University of Sheffield and we treated them whilst they were in Sheffield. We suspect they may have been treated elsewhere and the other Centres would have called them as being in the "at risk" group but I would be grateful if you could clarify this issue.

I look forward to hearing from you.

Kind regards

**GRO-C**

**M MAKRIS**

**Reader and Honorary Consultant in Haemostasis & Thrombosis**

Enc.

International Training Centre for the World Federation of Haemophilia